We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.2B
AUM Growth
+$1.6B
Cap. Flow
+$825M
Cap. Flow %
19.63%
Top 10 Hldgs %
44.15%
Holding
117
New
24
Increased
10
Reduced
49
Closed
12

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$207M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$150M
3
BCAB icon
BioAtla
BCAB
+$76.6M
4
CCCC icon
C4 Therapeutics
CCCC
+$72.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$48.8M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$61.3M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$50.2M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$35.5M
4
TWST icon
Twist Bioscience
TWST
+$30.5M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 78.9%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$292M 6.94%
2,392,297
-50,000
-2% -$5.48M
AVIR icon
2
Atea Pharmaceuticals
AVIR
$370M
$260M 6.18%
+6,411,355
New +$207M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$436B
$235M 5.6%
+750,000
New +$220M
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$211M 5.03%
1,500,000
+1,000,000
+200% +$128M
SPY icon
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$187M 4.45%
500,000
– –
BBIO icon
6
BridgeBio Pharma
BBIO
$16.4B
$161M 3.83%
2,265,762
– –
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$156M 3.7%
4,460,000
+1,080,627
+32% +$47M
OLMA icon
8
Olema Pharmaceuticals
OLMA
$977M
$148M 3.53%
+3,195,544
New +$150M
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$107M 2.54%
1,866,108
– –
RVMD icon
10
Revolution Medicines
RVMD
$38.5B
$98.8M 2.35%
2,495,066
-145,111
-5% -$5.74M
IWM icon
11
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$98M 2.33%
500,000
– –
STOK icon
12
Stoke Therapeutics
STOK
$1.84B
$89M 2.12%
1,437,807
-100,000
-7% -$4.58M
YMAB
13
DELISTED
Y-mAbs Therapeutics
YMAB
$82.3M 1.96%
1,661,647
+263,947
+19% +$12.2M
CCCC icon
14
C4 Therapeutics
CCCC
$389M
$80M 1.9%
+2,490,065
New +$72.2M
ALXO icon
15
ALX Oncology
ALXO
$262M
$76M 1.81%
881,770
-90,000
-9% -$5.41M
BEAM icon
16
Beam Therapeutics
BEAM
$2.68B
$75.5M 1.8%
924,249
+127,821
+16% +$6.29M
BCAB icon
17
BioAtla
BCAB
$5.34M
$75.4M 1.79%
+45,841
New +$76.6M
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$343M
$75.1M 1.79%
1,368,550
– –
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
$74.3M 1.77%
1,200,000
-200,000
-14% -$11.5M
IMVT icon
20
Immunovant
IMVT
$7.93B
$72.2M 1.72%
1,562,952
-74,999
-5% -$3.47M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$71.4M 1.7%
325,000
+50,000
+18% +$10.8M
TARS icon
22
Tarsus Pharmaceuticals
TARS
$2.55B
$70M 1.67%
+1,714,269
New +$48.8M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$62.9M 1.5%
2,464,547
-49,999
-2% -$1.46M
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$61.8M 1.47%
500,000
+50,000
+11% +$6.57M
PRAX icon
25
Praxis Precision Medicines
PRAX
$8.11B
$57.7M 1.37%
+71,610
New +$41.8M
1
2 3 4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Cormorant Asset Management held 117 positions worth $4.2B, up 62% from $2.6B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $825M of net new capital in Q4 2020, opening 24 new positions and adding to 10 existing holdings. Its largest new stake was Atea Pharmaceuticals: 6,411,355 shares worth $260M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $30.5M trimmed.

  • Cormorant Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 6,411,355 shares worth $260M.
  • Cormorant Asset Management added most to Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020, an estimated $47M increase.
  • Cormorant Asset Management's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $30.5M.
  • Cormorant Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $61.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $4.2B portfolio in Q4 2020.
  • Cormorant Asset Management opened 24 new positions and closed 12 in Q4 2020.
  • Cormorant Asset Management's portfolio value rose 62% quarter-over-quarter to $4.2B.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.